<DOC>
	<DOC>NCT00633048</DOC>
	<brief_summary>This is the first time that NSA-789, a new compound being developed for schizophrenia, will be given to humans. Each healthy subject will receive a single dose, except for 8 subjects who will receive 2 doses-- one dose under fasting conditions and one dose after eating food.</brief_summary>
	<brief_title>Study Evaluating the Safety and Tolerability of NSA-789</brief_title>
	<detailed_description />
	<criteria>Inclusion: Healthy men and women between 18 and 50 years old. Women must be of nonchildbearing potential (not able to have children). Must be of normal body weight.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>ascending single-dose study</keyword>
	<keyword>healthy subjects</keyword>
</DOC>